Pasireotide
Performance & EnduranceSecond-generation somatostatin analog with broader receptor binding for Cushings and acromegaly.
Key Benefits
- ✓Treats Cushings disease
- ✓Second-line for acromegaly
- ✓Broader receptor binding
- ✓Reduces ACTH secretion
- ✓Alternative when octreotide fails
Dosing Information
Detailed Protocol
Administered via subcutaneous injection twice daily (immediate) or intramuscular monthly depot. Requires close monitoring especially for hyperglycemia. Prescription only.
About Pasireotide
Pasireotide (Signifor) is a synthetic cyclohexapeptide somatostatin analog with high affinity for four of five somatostatin receptor subtypes. FDA-approved for Cushings disease and acromegaly when other treatments fail. More potent than octreotide.
Research Notes
FDA-approved for Cushings disease (2012) and acromegaly (2014). More effective than octreotide for Cushings but higher diabetes risk requires careful monitoring.
Potential Side Effects
- •Hyperglycemia (very common)
- •Diabetes development
- •Diarrhea
- •Nausea
- •Gallstones
- •Requires diabetes monitoring
Always consult with a healthcare professional before starting any peptide therapy.